Another Update with some more verbiage:
Second Rapid Viral Assay (RVA) Patent Granted
Technology can be configured to detect viruses including COVID19 and Variants, HIV, HPV, SARS, MERS, and others without limitation
We are pleased to announce the issuance of United States patent 11066712, "Rapid Viral Assay", for detection and diagnosis of COVID19 (SARS-2) and other viruses.
United States Patent: 11066712 (uspto.gov)
This is a Continuation-In-Part for the RVA Family of Technology initially granted with US Patent 10844442 on November 24, 2020
A further Continuation-In-Part application for an additional patent related to detection of spontanaeous viral mutations and other claims was filed with the USPTO yesterday. This addition will be essential to strengthening an already strong patent. We know that the virus will continue to mutate. It is extremely important that our tests are designed to anticipate that the virus will mutate and that the test will be able to detect the mutation.This approach is in stark contrast to current testing strategies, which may need to be modified to fit the mutation after the mutation occurs.
Full details of the granted patent, with the complete list of granted claims, is available in the USPTO Patent Gazette Week 29 publication.
This information can be accessed by entering the patent number of 11066712 after following this link: